Results 31 to 40 of about 4,164 (194)

Skeletal responses to romosozumab after 12 months of denosumab

JBMR Plus, 2021
Romosozumab, a monoclonal anti‐sclerostin antibody that has the dual effect of increasing bone formation and decreasing bone resorption, reduces fracture risk within 12 months.
Michael R. McClung, Michael A. Bolognese, Jacques P. Brown, Jean‐Yves Reginster, Bente L. Langdahl, Yifei Shi, Jen Timoshanko, Cesar Libanati, Arkadi Chines, Mary K. Oates   +9 more
doaj   +1 more source

New agents in the Treatment of Myeloma Bone Disease [PDF]

, 2017
Patients with multiple myeloma develop a devastating bone disease driven by the uncoupling of bone remodelling, excess osteoclastic bone resorption and diminished osteoblastic bone formation.
Chantry, A.D., Jolley, I., Lawson, M.A., Ring, E.S., Snowden, J.A.   +4 more
core   +2 more sources

Cardiovascular safety of antifracture medications in patients with osteoporosis: A narrative review of evidence from randomized studies [PDF]

, 2021
Osteoporosis and cardiovascular (CV) disease share common risk factors and pathophysiology. Low bone mineral density (BMD) and fractures appear to increase the risk for multiple CV diseases.
Abrahamsen, Bo, Rodríguez, Alexander J.
core   +2 more sources

Recommendations for The Conduct of Economic Evaluations in Osteoporosis: Outcomes of An Experts’ Consensus Meeting Organized by The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) And the US Branch of The International Osteoporosis Foundation [PDF]

, 2019
Summary Economic evaluations are increasingly used to assess the value of health interventions, but variable quality and heterogeneity limit the use of these evaluations by decision-makers.
Adachi, J.D., Al-Daghri, N., Bruyère, O., Bukata, S.V., Chandran, M., Cooper, C., Einhorn, T.A., Gold, D.T., Halbout, P., Harvey, N.C., Hiligsmann, M., Jiwa, F., Kanis, J.A., Kendler, D.L., Lewiecki, E.M., Messina, O.D., Osteoporosis Canada, Pinto, D., Reginster, J.-Y., Rizzoli, René, Saag, K.G., Si, L., Silverman, S., the Committee of Scientific Advisors and the Committee of National Societies of IOF, the Scientific Advisory Board of ESCEO, the US National Osteoporosis Foundation, Tosteson, A.N.A.   +26 more
core   +3 more sources

Clinical Utility of Romosozumab in the Management of Osteoporosis: Focus on Patient Selection and Perspectives

International Journal of Women's Health, 2022
Sian Yik Lim,1,2 Marcy B Bolster3 1Hawaii Pacific Health Medical Group, Honolulu, HI, USA; 2Department of Family Medicine, John E Burns School of Medicine, University of Hawaii, Honolulu, HI, USA; 3Division of Rheumatology, Allergy, and Immunology ...
Lim SY, Bolster MB
doaj  

WNT-mediated Modulation of Bone Metabolism: Implications for WNT Targeting to Treat Extraskeletal Disorders [PDF]

, 2017
The WNT-signaling pathway is involved in cellular and tissue functions that control such diverse processes as body axis patterning, cellular proliferation, differentiation, and life span.
Bullock, Whitney A., Robling, Alexander G.   +1 more
core   +1 more source

Favorable therapeutic response of osteoporosis patients to treatment with intravenous zoledronate compared with oral alendronate [PDF]

, 2015
Objectives: To evaluate the efficacy of orally-administered alendronate compared with intravenously-administered zoledronate. Methods: This prospective study was carried out at Barts Health HNS Trust between April 2010 and March 2012.
Akanle, OA, Al-Adhoubi, NK, Al-Bogami, MM, Alkhorayef, MA, Bystrom, J, Jawad, AS, Mageed, RA   +6 more
core   +4 more sources

Recent Developments in Osteogenesis Imperfecta [PDF]

, 2015
Osteogenesis imperfecta (OI) is an uncommon genetic bone disease associated with brittle bones and fractures in children and adults. Although OI is most commonly associated with mutations of the genes for type I collagen, many other genes (some ...
Albert, Carolyne, Fritz, Jessica M., Harris, Gerald F., Shaker, Joseph L.   +3 more
core   +2 more sources

Osteoporosis clinical practice guideline: romosozumab for treating severe osteoporosis – an update by the Egyptian Academy of Bone Health

Egyptian Rheumatology and Rehabilitation, 2022
Background This is a Clinical Practice Guideline update released by the Egyptian Academy of Bone Health and Metabolic Bone Diseases. It does not replace the clinical practice guidelines published for the treatment of osteoporosis in 2021, but it entails ...
Yasser El Miedany, Naglaa Ali Gadallah, Mathias Toth, Waleed Hassan, Maha Elgaafary, Mohamed Hassan, Mervat Eissa, Sally Saber, Walaa Elwakil, Safaa Mahran   +9 more
doaj   +1 more source

Pregnancy and Lactation-Associated Osteoporosis Successfully Treated with Romosozumab: A Case Report

Medicina, 2022
Pregnancy- and lactation-associated osteoporosis (PLO) is a rare type of premenopausal osteoporosis that occurs mainly in the third trimester or immediately after delivery; one of its most common symptoms is back pain caused by a vertebral fracture.
Yoichi Kaneuchi, Masumi Iwabuchi, Michiyuki Hakozaki, Hitoshi Yamada, Shin-ichi Konno   +4 more
doaj   +1 more source